AUTHORS
Tishira Shah, MS, Murugan Selvam, PhD2, Leslie Martinez-Gutierrez, MS3, Brian Buckley, BS4, Henry G. Withers, PhD5, Katerina Gurova, PhD6, Pamela J. Sung, MD PhD7
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Approximately 25% of acute myeloid leukemia (AML) cases have internal tandem duplications (ITD) mutations in fms-like tyrosine kinase 3 (FLT3) and are associated with higher rates of relapse. Currently available FLT3 inhibitors (FLT3i) like gilteritinib, quizartinib and midostaurin are FDA-approved therapies for FLT3-ITD patients. FLT3i have improved the overall survival rate in relapsed patients compared to salvage chemotherapy but only 16% of patients are still alive at 3 years. FLT3-ITD mutations lead to constitutive activation of FLT3 and its canonical downstream signaling pathways, PI3K/AKT/mTOR, RAS/MAPK, and STAT5. FLT3-ITD expression is highly enriched in stem-like cells suggesting that FLT3 has additional effects on cell differentiation. Clinical data demonstrate that FLT3i frequently induce differentiation responses, characterized by myeloid maturation with residual FLT3 clonal hematopoiesis (CH). Recent work published by our lab demonstrated that FLT3i downregulates enhancer of zeste homolog 2 (EZH2) protein stability as a mechanism of inducing myeloid differentiation in FLT3-ITD AML. However, the mechanism used by FLT3i to downregulate EZH2 is not yet known. FLT3-ITD CH is indicative of incomplete differentiation with persistent FLT3-ITD stem cell clones, which serve as a reservoir for relapse. With overt relapse, outgrowth of acquired NRAS/KRAS mutations frequently arises as a mechanism of resistance to FLT3i treatment. One-third of FLT3-ITD AML patients undergoing gilteritinib therapy, including those with differentiation response, have acquired RAS mutations in FLT3-ITD mutated subclones. Thus, there is an urgent need to develop better therapeutic strategies to augment terminal myeloid differentiation to clear the FLT3-ITD stem cell clone. Therefore, it is critical to understand the mechanism used by FLT3i to promote differentiation through downregulation of EZH2.
We performed a kinase inhibitor drug screen in a FLT3-ITD mutant cell line (MOLM14) expressing an exogenous GFP-tagged EZH2 from a constitutive promoter and identified three out of four available IκB kinase (IKK) inhibitors in the library as top hits downregulating GFP-EZH2 signal. IKKs form the IKK complex (IKK1, IKK2, and NEMO), which activates NFκB through phosphorylation and leads to proteasomal degradation of IκB. A FLT3i (TCS359) also screened positively for decreasing GFP-EZH2 signal, thus validating our approach. Drug screening results were validated with a pan-IKK inhibitor, IKK16, in two FLT3-ITD AML cell lines: MOLM14 and MV4;11. Both cell lines showed a dose-dependent decrease in endogenous EZH2 protein by IKK16. Additionally, overexpression of a dominant negative IKK2 mutant in MOLM14 was sufficient to downregulate EZH2. Treatment with IKK16 did not alter EZH2 transcript levels as measured by qPCR. Thus, IKK regulates EZH2 at the protein level. Moreover, the decrease of EZH2 protein by IKK inhibition was FLT3-ITD mutant specific as no effects on EZH2 were observed in FLT3 wild-type cell lines, THP-1 and KG-1. Gilteritinib treatment showed decreased phospho-IKK in MOLM14 and MV4;11 cells, suggesting that FLT3-ITD regulates EZH2 via IKK signaling. As RAS mutations confer resistance to FLT3i, we evaluated its role in EZH2 downregulation with FLT3i. FLT3i resistant MOLM14 cells expressing either NRAS G12C or NRAS Q61K mutation, thus, preserve EZH2 expression after gilteritinib treatment. Doxycycline-induced expression of mutant NRAS in MOLM14 cells showed similar findings, indicating RAS activation is sufficient to protect EZH2 from downregulation by FLT3i. Using cycloheximide chase assays, we demonstrated that RAS activation protects EZH2 from FLT3i-induced protein instability. Importantly, IKK inhibition also decreased EZH2 expression even in RAS co-mutated cell lines, indicating that IKK functions downstream of RAS activation. Direct inhibition of mutant NRAS with the pan-RAS inhibitor, RMC-7977, showed only modest reductions in EZH2 expression, demonstrating that RAS is sufficient but not necessary for EZH2 regulation. Additional pathways along with RAS signaling regulating EZH2 protein are under investigation. Overall, our results establish a FLT3-RAS-IKK-EZH2 axis in FLT3-ITD AML for inducing terminal myeloid differentiation. Functional studies validating the role of RAS-IKK signaling in regulating EZH2 to induce myeloid differentiation are planned in FLT3 AML mouse models.
DISCLOSURES
Tishira Shah, MS: No relevant conflicts of interest to declare.